GH Secretagogue Receptors Found in Both Normal and Cancerous Human Thyroid Tissue
Specific GH secretagogue binding sites were detected in normal human thyroid tissue and in thyroid cancers, with higher density in medullary thyroid carcinoma, raising questions about GH peptide effects on the thyroid.
Quick Facts
What This Study Found
Specific GHS binding sites were detected in normal and neoplastic human thyroid tissue, with highest density in medullary thyroid carcinoma, suggesting GH secretagogues may affect thyroid biology and that GHS-R could serve as a thyroid cancer marker.
Key Numbers
How They Did This
In-vitro binding study using 125I-Tyr-Ala-hexarelin on membrane preparations from normal human thyroid and various thyroid tumors. Binding affinity and density characterized across tissue types.
Why This Research Matters
If GH secretagogues affect the thyroid, this has safety implications for people using these peptides. Additionally, elevated GHS-R in thyroid cancer could serve as a diagnostic or therapeutic target.
The Bigger Picture
GH secretagogue receptors are being found in an increasing number of tissues beyond the pituitary. Each new location raises questions about both therapeutic opportunities and safety considerations.
What This Study Doesn't Tell Us
In-vitro binding study. Functional consequences of GHS-R activation in thyroid tissue were not tested. Limited tumor sample numbers.
Questions This Raises
- ?Could GH secretagogue use affect thyroid function or thyroid nodule growth?
- ?Can GHS-R imaging detect thyroid cancers?
- ?Does GHS-R activation promote or inhibit thyroid cancer cell growth?
Trust & Context
- Key Stat:
- Highest in medullary carcinoma GHS receptor density was highest in medullary thyroid cancer, suggesting potential as a diagnostic marker or therapeutic target
- Evidence Grade:
- Preliminary in-vitro binding evidence in human tissue providing clear receptor characterization data across thyroid tissue types.
- Study Age:
- Published in 2000. The clinical significance of GHS-R in thyroid tissue continues to be investigated.
- Original Title:
- Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue.
- Published In:
- The Journal of endocrinology, 165(1), 139-46 (2000)
- Authors:
- Cassoni, P(3), Papotti, M(8), Catapano, F(3), Ghè, C, Deghenghi, R, Ghigo, E, Muccioli, G
- Database ID:
- RPEP-00585
Evidence Hierarchy
Frequently Asked Questions
Should GH peptide users worry about their thyroid?
This study shows GH peptide receptors exist in thyroid tissue, but whether activating them has clinically significant effects on the thyroid is unknown. It's worth noting but not a proven concern.
Could this help detect thyroid cancer?
Possibly. The high receptor density in medullary thyroid carcinoma suggests GHS-R-targeted imaging could potentially detect this cancer type. This needs clinical validation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00585APA
Cassoni, P; Papotti, M; Catapano, F; Ghè, C; Deghenghi, R; Ghigo, E; Muccioli, G. (2000). Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue.. The Journal of endocrinology, 165(1), 139-46.
MLA
Cassoni, P, et al. "Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue.." The Journal of endocrinology, 2000.
RethinkPeptides
RethinkPeptides Research Database. "Specific binding sites for synthetic growth hormone secretag..." RPEP-00585. Retrieved from https://rethinkpeptides.com/research/cassoni-2000-specific-binding-sites-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.